Ibrahim Aldoss
City of Hope Medical Center · SWOG Cancer Research Network · City of Hope Medical Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ibrahim Aldoss as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:51 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07758673 · Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic LymphomaCity of Hope Medical Center · not yet recruiting · Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT07636564 · Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentSWOG Cancer Research Network · not yet recruiting · Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative · principal investigator
- Ph1NCT07040982 · Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCity of Hope Medical Center · recruiting · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · principal investigator
- Ph2NCT06918431 · Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCity of Hope Medical Center · recruiting · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma · principal investigator
- Early Ph1NCT06735690 · Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic LeukemiaCity of Hope Medical Center · recruiting · Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT06447987 · Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic LeukemiaCity of Hope Medical Center · suspended · Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT05707273 · CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First RemissionCity of Hope Medical Center · active not recruiting · B Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT04690595 · BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALLPeproMene Bio, Inc. · active not recruiting · Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT03739606 · Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerCity of Hope Medical Center · withdrawn · Acute Biphenotypic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
- Ph1NCT02146924 · Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic LeukemiaCity of Hope Medical Center · active not recruiting · B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- BAFF-R CAR T cell therapy for ALLR01CA269569 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2022 to 2026 · $677,623 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2010 to 2026
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT07636564
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:51 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- 475 citationsRCR 40.0
- 281 citationsRCR 14.8
- Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).J Clin Oncol · 2025236 citationsRCR 60.4
- Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.Am J Hematol · 2017143 citationsRCR 4.1
- 116 citationsRCR 13.6
- Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.J Clin Oncol · 2014104 citationsRCR 3.3
- 102 citationsRCR 6.4
- Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.Biol Blood Marrow Transplant · 201779 citationsRCR 3.1
- 79 citationsRCR 18.7
- 73 citationsRCR 2.6